Sensitization Challenge Phase Testing for Medical Devices: Principles, Methods, and ISO 10993-10 Com

The medical device sensitization challenge phase test is the critical second stage of in vivo delayed-type hypersensitivity evaluation, verifying whether a device or its extract can elicit an allergic skin response after immune priming. Conducted in accordance with ISO 10993-10 and GB/T 16886.10, the challenge phase distinguishes true sensitization from simple irritation and generates essential biocompatibility data for global regulatory submissions. This article explains the technical principles, sample requirements, testing items, methods, and applications of the sensitization challenge phase test.

Technical Overview

The sensitization challenge phase test, also known as the elicitation phase, is the concluding and decisive stage of a two-part in vivo skin sensitization evaluation for medical devices. During the preceding induction phase, test animals are repeatedly or intensively exposed to a device extract to stimulate the adaptive immune system. After a rest period of approximately two weeks that allows immune memory to develop, the challenge phase re-exposes the animals to the same extract at a non-irritating concentration. The appearance of erythema or edema at the challenge site, in the absence of reactions in challenge-only control animals, indicates that type IV delayed hypersensitivity has been induced.

Scientific Principle

Sensitization is a two-step immunological process. The induction phase activates T-lymphocytes and establishes immunological memory, while the challenge phase demonstrates that this memory can be triggered by subsequent contact. Because the challenge concentration is deliberately selected to be non-irritating, any skin reaction observed during this phase is attributable to an allergic mechanism rather than direct chemical irritation, providing a clear mechanistic distinction between the two response types.

Regulatory and Standards Basis

The test is performed in accordance with ISO 10993-10, Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization, and its Chinese counterpart GB/T 16886.10. Sample preparation follows ISO 10993-12 and GB/T 16886.12, while the overall test strategy is selected based on the contact categorization defined in ISO 10993-1. The guinea pig maximization test and the Buehler test described in these standards both incorporate a mandatory challenge phase as their endpoint.

Testing Samples

Device Categories

Sensitization testing, including the challenge phase, is typically required for medical devices that contact intact skin, mucous membranes, breached or compromised surfaces, blood, or tissue, as determined by the biological evaluation plan. Common product categories include:

• Surface-contacting devices such as surgical gloves, wound dressings, adhesive tapes, electrodes, and compression bandages
• External communicating devices such as catheters, infusion sets, syringes, endotracheal tubes, and dental appliances
• Implantable devices such as orthopedic implants, cardiac devices, and absorbable materials
• Devices containing known potential sensitizers, including natural rubber latex, residual monomers, accelerators, metal ions such as nickel and chromium, and sterilization residues such as ethylene oxide

Extract Preparation

Because most finished devices cannot be applied directly to animal skin in a standardized manner, test samples are usually prepared as aqueous and organic extracts. In accordance with ISO 10993-12, extraction is performed using a polar solvent such as sodium chloride injection or water, and a non-polar solvent such as sesame oil or cottonseed oil, at standardized surface-area-to-volume or mass-to-volume ratios. Standard extraction conditions include 37 degrees Celsius for 72 hours, with justification required for alternative conditions. The resulting extracts are used for both the induction and challenge applications.

Testing Items

The challenge phase generates a defined set of observations and data points that together determine whether sensitization has occurred. The principal items evaluated include:

• Skin reaction grading at the challenge sites of test animals at 24 hours and 48 hours after patch removal, using the Magnusson-Kligman scale
• Skin reaction grading at the challenge sites of naive, challenge-only control animals to confirm that the challenge concentration is non-irritating
• Incidence and intensity comparison between the test group and the control group
• Assessment of body weight, clinical signs, and mortality throughout the observation period
• Documentation of desquamation, hyperkeratosis, or other delayed skin changes where relevant
• Evaluation of positive control responsiveness of the test system at defined intervals

The Magnusson-Kligman grading scale assigns a score of 0 for no visible change, 1 for discrete or patchy erythema, 2 for moderate and confluent erythema, and 3 for intense erythema and swelling. A response is generally interpreted as sensitization when test animals exhibit reactions that are absent or markedly weaker in the challenge-only control animals.

Testing Methods

Guinea Pig Maximization Test Challenge Procedure

The guinea pig maximization test is the most sensitive standard method and typically employs Dunkin-Hartley guinea pigs, with a minimum of 10 test animals and 5 naive control animals. After the intradermal induction on day 0 and the topical induction on approximately day 6, followed by a rest period of about two weeks, the challenge is performed around day 20. A filter paper patch saturated with the test extract at the highest non-irritating concentration is applied occlusively to the shaved flank for 24 hours. Skin reactions are graded at 24 hours and 48 hours after patch removal. If reactions occur in the control animals, the response is attributed to irritation, and the study design must be reconsidered.

Buehler Test Challenge Procedure

The Buehler test is a closed-patch, epicutaneous method suitable for devices that contact intact skin and for materials that are directly applicable to the skin surface. Following three weekly six-hour occlusive induction exposures, the animals rest for approximately two weeks. The challenge consists of a single six-hour occlusive patch application of the test extract or test material at a non-irritating level, after which the challenge sites are graded at 24 hours and 48 hours, with additional observations at 72 hours when necessary.

Re-Challenge and Confirmation

When challenge results are equivocal, or when control animals unexpectedly show reactions, a re-challenge may be performed after a further rest period, typically on the contralateral flank and sometimes at a reduced concentration. The re-challenge serves to confirm positive findings, resolve ambiguous grading, and demonstrate the specificity of the elicitation response. Documentation of re-challenge conditions and results forms an integral part of the final study report.

Local Lymph Node Assay Consideration

The murine local lymph node assay is an accepted alternative that measures lymphocyte proliferation during the induction phase and does not include a challenge phase. Laboratories may select this method for animal welfare reasons under ISO 10993-2 principles, but studies requiring direct demonstration of elicitation, or submissions guided by certain regional expectations, continue to rely on the guinea pig challenge-phase design.

Applications

Challenge phase data from sensitization studies support a wide range of regulatory and engineering purposes across the medical device industry. Key applications include:

• Biological safety evaluation reports for device registration submissions in major markets, including national medical device administration filings, premarket notifications, and conformity assessment under regional regulations
• Technical documentation files supporting compliance with the ISO 10993 series of standards
• Verification of biological safety after material changes, supplier changes, manufacturing process modifications, or changes in sterilization method
• Screening of new polymers, coatings, adhesives, and elastomers during research and development
• Risk assessment support when chemical characterization identifies leachable substances with sensitizing potential

Accredited third-party laboratories routinely conduct these studies under Good Laboratory Practice principles, providing regulatory-grade protocols, raw data traceability, and comprehensive final reports suitable for submission to competent authorities worldwide.

FAQ

What is the difference between the induction phase and the challenge phase?

The induction phase exposes the animal to the test extract in a manner designed to activate the immune system and create immunological memory, often with the aid of adjuvant in the maximization test. The challenge phase then re-exposes the sensitized animal to a non-irritating concentration of the same extract to determine whether an elicitation response, namely erythema or edema, occurs. Only the challenge phase demonstrates that sensitization has actually been established.

Why are challenge-only control animals necessary?

Control animals receive only the challenge application without prior induction. If these naive animals show no reaction while the test group reacts, the response can be attributed to sensitization. If control animals also react, the challenge concentration is irritant and the result cannot be interpreted as sensitization, which is why control animals are indispensable to the validity of the test.

How long does the complete sensitization study take?

For the guinea pig maximization test, the in-life phase from induction to final challenge observation generally spans approximately four to five weeks, and the complete study including acclimatization, extract preparation, and reporting typically requires six to eight weeks. Buehler tests follow a similar overall timeline.

What does a positive challenge phase result mean for a device?

A positive result indicates that the device extract has sensitizing potential under the conditions of the test. This triggers a benefit-risk evaluation that may include chemical analysis of the responsible leachables, material substitution, process modification, or labeled warnings, as determined by the biological evaluation risk assessment process defined in ISO 10993-1.

Can the challenge phase be waived for any devices?

Where a device is demonstrated to be identical in materials, manufacturing, and sterilization to a previously evaluated predicate, or where toxicological risk assessment based on chemical characterization concludes an acceptable margin of safety, sensitization testing may be justified by existing data. Such waivers must be documented and scientifically defended within the biological evaluation file.